[1] Riehle KJ, Vasudevan SA, Bondoc A, et al. Surgical management of liver tumors. Pediatr Blood Cancer,2024,2:e31155. [2] 杨帆,杨军,濮忠健,等.TACE术后联合斑蝥酸钠维生素B6治疗原发性肝癌患者近期疗效研究.实用肝脏病杂志,2024,27(2):263-266. [3] Giri S, Singh A. Epidemiology of hepatocellular carcinoma in India-an updated review for 2024. J Clin Exp Hepatol,2024,14(6):101447-101452. [4] 袁振刚,叶胜龙.肝细胞癌系统治疗策略:现状和前景.中华肝脏病杂志,2024,32(6):565-571. [5] Zhou J, Liu Y, Ren Z, et al. Transarterial chemoembolization with gelatin sponge microparticles for Barcelona clinic liver cancer stage c and large hepatocellular carcinoma: Initial clinical experience. J Cancer Res Ther,2017,13(5):767-772. [6] Shi Y, Taherifard E, Saeed A, et al. MASLD-related HCC: a comprehensive review of the trends, pathophysiology, tumor microenvironment, surveillance, and treatment options. Curr Issues Mol Biol,2024,46(6):5965-5983. [7] Bianchi V, Nure E, Nesci C, et al. Bridge therapy before liver transplant for advanced hepatocellular carcinoma. Medicina (Kaunas),2024,60(6):1010-1018. [8] 刘华江,邓堂,金桂云.较大体积肝癌肝动脉化疗栓塞联合微波消融或射频消融治疗82例对比观察.中华肿瘤防治杂志,2020,27(18):1522-1528. [9] Yi PS, Huang M, Zhang M, et al. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am Surg,2018,84(2):282-288. [10] Galanakis N, Kehagias E, Matthaiou N, et al. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol,2018,5(2):HEP07. [11] Wang C, Chen C, Hu W, et al. Revealing the role of necroptosis microenvironment: FCGBP+tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Apoptosis,2024,29(3-4):460-481. [12] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版).中华消化病与影像杂志(电子版),2020,10(1):22-48. [13] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol,2017,18(3):143-152. [14] 翟会专,李增军,王东洋,等.肝癌患者导管肝动脉化疗栓塞术疗效与免疫指标临床观察.中华肿瘤防治杂志,2020,27(22):1827-1831. [15] Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev,2019,72:28-36. [16] Guo JY, Zhao LL, Cai HJ, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer. World J Gastrointest Surg,2024,16(6):1756-1764. [17] Osman A, Patel S, Gonsalves M, et al. Vascular interventions in oncology. Clin Oncol (R Coll Radiol),2024,36(8):473-483. [18] Dan Y, Meng W, Li W, et al. Transarterial chemoembolization combined with radiofrequency ablation versus hepatectomy for hepatocellular carcinoma: a meta-analysis. Front Surg,2022,9:948355. [19] Shao Y, Chen T, Zheng X, et al. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis,2018,39(11):1368-1379. [20] Chen Z, Guo P, Xie X, et al. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med,2019,23(1):59-69. |